NBTX
NanobiotixFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Positive pivotal/clinical outcomes and a clear regulatory path drive rapid re-rating; partnerships or licensing could accelerate adoption.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Failed pivotal trial or negative clinical data
Momentum
34
Value
41
Sentiment
7
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.53 · Bull $32.30 · Bear $8.61
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $54.34
Why
Momentum34 · Δ7d -2.8
Value41 · Δ7d +0.0
Sentiment7 · Δ7d +2.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
34
26% active weight
Current posture
7d trendFlat
Δ7d
-2.8
Δ21d
-6.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
7
34% active weight
Current posture
7d trendImproving
Δ7d
+2.1
Δ21d
-4.3
Why this grade
Composite grade F. Momentum 34.1 / Value 41.1 / Sentiment 6.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.91B
Beta
0.18
Shares Out
50.6M
P/E (TTM) · Derived
-66.6
P/S (TTM)
89.51
P/FCF (TTM) · Derived
-43.63
Rev YoY
-39.5%
EPS YoY
+75.5%
Gross Margin
-35.7%
Op Margin
-597.9%
Net Debt
$50M
Current Ratio
1.09
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology